282 related articles for article (PubMed ID: 30086056)
21. Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency.
Bourdais R; Rousseau B; Pujals A; Boussion H; Joly C; Guillemin A; Baumgaertner I; Neuzillet C; Tournigand C
Crit Rev Oncol Hematol; 2017 May; 113():242-248. PubMed ID: 28427513
[TBL] [Abstract][Full Text] [Related]
22. Germline and somatic polymerase ε and δ mutations define a new class of hypermutated colorectal and endometrial cancers.
Briggs S; Tomlinson I
J Pathol; 2013 Jun; 230(2):148-53. PubMed ID: 23447401
[TBL] [Abstract][Full Text] [Related]
23. The clinical features of polymerase proof-reading associated polyposis (PPAP) and recommendations for patient management.
Palles C; Martin L; Domingo E; Chegwidden L; McGuire J; Cuthill V; Heitzer E; ; Kerr R; Kerr D; Kearsey S; Clark SK; Tomlinson I; Latchford A
Fam Cancer; 2022 Apr; 21(2):197-209. PubMed ID: 33948826
[TBL] [Abstract][Full Text] [Related]
24. Nucleotide selectivity defect and mutator phenotype conferred by a colon cancer-associated DNA polymerase δ mutation in human cells.
Mertz TM; Baranovskiy AG; Wang J; Tahirov TH; Shcherbakova PV
Oncogene; 2017 Aug; 36(31):4427-4433. PubMed ID: 28368425
[TBL] [Abstract][Full Text] [Related]
25. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.
Domingo E; Freeman-Mills L; Rayner E; Glaire M; Briggs S; Vermeulen L; Fessler E; Medema JP; Boot A; Morreau H; van Wezel T; Liefers GJ; Lothe RA; Danielsen SA; Sveen A; Nesbakken A; Zlobec I; Lugli A; Koelzer VH; Berger MD; Castellví-Bel S; Muñoz J; ; de Bruyn M; Nijman HW; Novelli M; Lawson K; Oukrif D; Frangou E; Dutton P; Tejpar S; Delorenzi M; Kerr R; Kerr D; Tomlinson I; Church DN
Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):207-216. PubMed ID: 28404093
[TBL] [Abstract][Full Text] [Related]
26. The burden of faulty proofreading in colon cancer.
Seshagiri S
Nat Genet; 2013 Feb; 45(2):121-2. PubMed ID: 23358219
[TBL] [Abstract][Full Text] [Related]
27. A novel germline POLE mutation causes an early onset cancer prone syndrome mimicking constitutional mismatch repair deficiency.
Wimmer K; Beilken A; Nustede R; Ripperger T; Lamottke B; Ure B; Steinmann D; Reineke-Plaass T; Lehmann U; Zschocke J; Valle L; Fauth C; Kratz CP
Fam Cancer; 2017 Jan; 16(1):67-71. PubMed ID: 27573199
[TBL] [Abstract][Full Text] [Related]
28. Tumor-Infiltrating Lymphocytes, Tumor Mutational Burden, and Genetic Alterations in Microsatellite Unstable, Microsatellite Stable, or Mutant
Keshinro A; Vanderbilt C; Kim JK; Firat C; Chen CT; Yaeger R; Ganesh K; Segal NH; Gonen M; Shia J; Stadler Z; Weiser MR
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250404
[TBL] [Abstract][Full Text] [Related]
29. Germline PMS2 and somatic POLE exonuclease mutations cause hypermutability of the leading DNA strand in biallelic mismatch repair deficiency syndrome brain tumours.
Andrianova MA; Chetan GK; Sibin MK; Mckee T; Merkler D; Narasinga RK; Ribaux P; Blouin JL; Makrythanasis P; Seplyarskiy VB; Antonarakis SE; Nikolaev SI
J Pathol; 2017 Nov; 243(3):331-341. PubMed ID: 28805995
[TBL] [Abstract][Full Text] [Related]
30. DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer.
Church DN; Briggs SE; Palles C; Domingo E; Kearsey SJ; Grimes JM; Gorman M; Martin L; Howarth KM; Hodgson SV; ; Kaur K; Taylor J; Tomlinson IP
Hum Mol Genet; 2013 Jul; 22(14):2820-8. PubMed ID: 23528559
[TBL] [Abstract][Full Text] [Related]
31. DNA Polymerase ɛ Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity.
Castellucci E; He T; Goldstein DY; Halmos B; Chuy J
Oncologist; 2017 May; 22(5):497-502. PubMed ID: 28465371
[TBL] [Abstract][Full Text] [Related]
32. Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity.
Ma X; Riaz N; Samstein RM; Lee M; Makarov V; Valero C; Chowell D; Kuo F; Hoen D; Fitzgerald CWR; Jiang H; Alektiar J; Alban TJ; Juric I; Parthasarathy PB; Zhao Y; Sabio EY; Verma R; Srivastava RM; Vuong L; Yang W; Zhang X; Wang J; Chu LK; Wang SL; Kelly DW; Pei X; Chen J; Yaeger R; Zamarin D; Zehir A; Gönen M; Morris LGT; Chan TA
Nat Genet; 2022 Jul; 54(7):996-1012. PubMed ID: 35817971
[TBL] [Abstract][Full Text] [Related]
33. POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes.
Magrin L; Fanale D; Brando C; Fiorino A; Corsini LR; Sciacchitano R; Filorizzo C; Dimino A; Russo A; Bazan V
Oncogene; 2021 Oct; 40(40):5893-5901. PubMed ID: 34363023
[TBL] [Abstract][Full Text] [Related]
34. The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy.
Ahn SM; Ansari AA; Kim J; Kim D; Chun SM; Kim J; Kim TW; Park I; Yu CS; Jang SJ
Oncotarget; 2016 Oct; 7(42):68638-68649. PubMed ID: 27612425
[TBL] [Abstract][Full Text] [Related]
35. Germline
Lindsay H; Scollon S; Reuther J; Voicu H; Rednam SP; Lin FY; Fisher KE; Chintagumpala M; Adesina AM; Parsons DW; Plon SE; Roy A
Cold Spring Harb Mol Case Stud; 2019 Oct; 5(5):. PubMed ID: 31624068
[TBL] [Abstract][Full Text] [Related]
36. Duodenal Adenomas in Patients With Multiple Colorectal Adenomas Without Germline APC or MUTYH Mutations.
Kallenberg FGJ; Latchford A; Lips NC; Aalfs CM; Bastiaansen BAJ; Clark SK; Dekker E
Dis Colon Rectum; 2018 Jan; 61(1):58-66. PubMed ID: 29215473
[TBL] [Abstract][Full Text] [Related]
37. Mutation analysis of POLE gene in patients with early-onset colorectal cancer revealed a rare silent variant within the endonuclease domain with potential effect on splicing.
Lasabová Z; Kalman M; Holubeková V; Grendár M; Kašubová I; Jašek K; Meršaková S; Malicherová B; Baranenko D; Adamek M; Kruzliak P; Plank L
Clin Exp Med; 2019 Aug; 19(3):393-400. PubMed ID: 31049795
[TBL] [Abstract][Full Text] [Related]
38. Role of POLE and POLD1 in familial cancer.
Mur P; García-Mulero S; Del Valle J; Magraner-Pardo L; Vidal A; Pineda M; Cinnirella G; Martín-Ramos E; Pons T; López-Doriga A; Belhadj S; Feliubadaló L; Munoz-Torres PM; Navarro M; Grau E; Darder E; Llort G; Sanz J; Ramón Y Cajal T; Balmana J; Brunet J; Moreno V; Piulats JM; Matías-Guiu X; Sanz-Pamplona R; Aligué R; Capellá G; Lázaro C; Valle L
Genet Med; 2020 Dec; 22(12):2089-2100. PubMed ID: 32792570
[TBL] [Abstract][Full Text] [Related]
39. Common MUTYH mutations and colorectal cancer risk in multiethnic populations.
Lejbkowicz F; Cohen I; Barnett-Griness O; Pinchev M; Poynter J; Gruber SB; Rennert G
Fam Cancer; 2012 Sep; 11(3):329-35. PubMed ID: 22371070
[TBL] [Abstract][Full Text] [Related]
40. Germline mutation p.N363K in POLE is associated with an increased risk of colorectal cancer and giant cell glioblastoma.
Vande Perre P; Siegfried A; Corsini C; Bonnet D; Toulas C; Hamzaoui N; Selves J; Chipoulet E; Hoffmann JS; Uro-Coste E; Guimbaud R
Fam Cancer; 2019 Apr; 18(2):173-178. PubMed ID: 30368636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
